Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Association between Cigarette Smoking and RASSF1A Gene Promoter Hypermethylation in Lung Cancer Patients: a Meta-analysis

  • Wu, Xiao-Ming (Laboratory of Molecular Genetics of Aging and Tumor, Medical Faculty, Kunming University of Science and Technology) ;
  • Chen, Yu (Laboratory of Molecular Genetics of Aging and Tumor, Medical Faculty, Kunming University of Science and Technology) ;
  • Shao, Yang (Laboratory of Molecular Genetics of Aging and Tumor, Medical Faculty, Kunming University of Science and Technology) ;
  • Zhou, Xiao-Long (Laboratory of Molecular Genetics of Aging and Tumor, Medical Faculty, Kunming University of Science and Technology) ;
  • Tang, Wen-Ru (Laboratory of Molecular Genetics of Aging and Tumor, Medical Faculty, Kunming University of Science and Technology)
  • Published : 2014.10.23
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: Epidemiological studies have shown that molecular mechanisms underlying the development of lung cancers differ between smokers and unsmokers. Aberrant promoter methylation in some tumor suppressor genes is frequent in lung tumors from smokers but rare in those from non-smokers. Recently, many studies have investigated the association between cigarette smoking and RASSF1A gene promoter hypermethylation in lung cancer patients, but a unanimous conclusion could not be reached. We therefore performed this meta-analysis to derive a more precise estimation of any association. Study Design: An electronic search of PubMed and Chinese Biomedicine databases was conducted to select studies. A total of 19 case-control studies were chosen, and odds ratios (ORs) with confidence intervals (CIs) were used to assess the strength of associations. Results: The case-control studies covered 2, 287 lung cancer patients: 63.4%(1449) of the patients were smokers, 36.6% (838) were unsmokers. The overall results suggested that smokers with lung cancer had a 1.297-fold (95% CI: 1.066~1.580, p=0.010, p=0.087) higher risk for RASSF1A gene hypermethylation than the non-smokers. In the stratified analysis, an increased risk of RASSF1A gene hypermethylation in smokers than in non-smokers was found in Asian (OR=1.481, 95%CI: 1.179~1.861, p=0.001, p=0.186). Conclusions: This meta-analysis supports the idea that RASSF1A gene hypermethylation is associated with cigarette smoking-induced lung cancer.

Keywords

References

  1. Burbee DG, Forgacs E, Zochbauer-Muller S, et al (2001). Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst, 93, 691-9. https://doi.org/10.1093/jnci/93.9.691
  2. Dammann R, Li C, Yoon JH, et al (2000). Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet, 25, 315-9. https://doi.org/10.1038/77083
  3. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  4. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  5. Endoh H, Yatabe Y, Shimizu S, et al (2003). RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication. Int J Cancer, 106, 45-51. https://doi.org/10.1002/ijc.11184
  6. Ge YZ, Xu LW, Jia RP, et al (2014). The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies. Tumour Biol, 35, 3881-90. https://doi.org/10.1007/s13277-013-1515-3
  7. Grote HJ, Schmiemann V, Geddert H, et al (2006). Methylation of RAS association domain family protein 1A as a biomarker of lung cancer. Cancer, 108, 129-34. https://doi.org/10.1002/cncr.21717
  8. Hesson LB, Cooper WN, Latif F (2007). The role of RASSF1A methylation in cancer. Dis Markers, 23, 73-87. https://doi.org/10.1155/2007/291538
  9. Honorio S, Agathanggelou A, Schuermann M, et al (2003). Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene, 22, 147-50. https://doi.org/10.1038/sj.onc.1206057
  10. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  11. Khokhlatchev A, Rabizadeh S, Xavier R, et al (2002). Identification of a novel Ras-regulated proapoptotic pathway. Curr Biol, 12, 253-65. https://doi.org/10.1016/S0960-9822(02)00683-8
  12. Kim DH, Kim JS, Ji YI, et al (2003). Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res, 63, 3743-6.
  13. Lin RK, Hsieh YS, Lin P, et al (2010). The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J Clin Invest, 120, 521-32. https://doi.org/10.1172/JCI40706
  14. Lin RK, Hsu HS, Chang JW, et al (2007). Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer. Lung Cancer, 55, 205-13. https://doi.org/10.1016/j.lungcan.2006.10.022
  15. Liu L, Tommasi S, Lee DH, et al (2003). Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene, 22, 8125-36. https://doi.org/10.1038/sj.onc.1206984
  16. Liu WJ, Tan XH, Guo BP, et al (2013). Associations between RASSF1A promoter methylation and NSCLC: a metaanalysis of published data. Asian Pac J Cancer Prev, 14, 3719-24. https://doi.org/10.7314/APJCP.2013.14.6.3719
  17. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  18. Mathe E (2004). RASSF1A, the new guardian of mitosis. Nat Genet, 36, 117-8. https://doi.org/10.1038/ng0204-117
  19. Shivakumar L, Minna J, Sakamaki T, et al (2002). The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol, 22, 4309-18. https://doi.org/10.1128/MCB.22.12.4309-4318.2002
  20. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  21. Tomizawa Y, Kohno T, Kondo H, et al (2002). Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res, 8, 2362-8.
  22. Villeneuve PJ, Mao Y (1994). Lifetime probability of developing lung cancer, by smoking status, Canada. Can J Public Health, 85, 385-8.
  23. Vo LT, Thuan TB, Thu DM, et al (2013). Methylation profile of BRCA1, RASSF1A and ER in Vietnamese women with ovarian cancer. Asian Pac J Cancer Prev, 14, 7713-8. https://doi.org/10.7314/APJCP.2013.14.12.7713
  24. Wang SH, Liu NH, Wang J, et al (2008). Critical role of deltaDNMT3B4/2 in regulating RASSF1A promoter-specific DNA methylation in non-small cell lung cancer. Chin Med J (Engl), 121, 1712-21.
  25. Zochbauer-Muller S, Fong KM, Virmani AK, et al (2001). Aberrant promoter methylation of multiple genes in nonsmall cell lung cancers. Cancer Res, 61, 249-55.

Cited by

  1. Association of Methylation of the RAR-β Gene with Cigarette Smoking in Non-Small Cell Lung Cancer with Southern-central Chinese Population vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10937
  2. The Indirect Efficacy Comparison of DNA Methylation in Sputum for Early Screening and Auxiliary Detection of Lung Cancer: A Meta-Analysis vol.14, pp.7, 2017, https://doi.org/10.3390/ijerph14070679